BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares after its Q4 results. The company is firing on all cylinders amd is a leading growth story in specialty labs, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- 3 ‘Strong Buy’ Stocks to Buy Now, 2/6/2026, According to Top Analysts
- Adaptive Biotechnologies price target raised to $21 from $20 at JPMorgan
- Adaptive Biotechnologies: Sustained MRD Growth, Pricing Power, and Strategic Positioning Support Buy Rating and Premium Valuation
- Adaptive Biotechnologies: Strong MRD Momentum, Enhanced 2026 Outlook, and Clear Path to Profitability Support Buy Rating
- Adaptive Biotechnologies reports Q4 EPS (9c), consensus (18c)